GBT:NSD-Global Blood Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 66.75

Change

0.00 (0.00)%

Market Cap

USD 4.50B

Volume

5.76M

Avg Analyst Target

USD 66.53 (-0.32%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


GBT Stock Forecast & Price:
Based on the Global Blood Therapeutics Inc stock forecasts from 14 analysts, the average analyst target price for Global Blood Therapeutics Inc is USD 66.53 over the next 12 months. Global Blood Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Global Blood Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Global Blood Therapeutics Inc’s stock price was USD 66.75. Global Blood Therapeutics Inc’s stock price has changed by +4.56% over the past week, +92.20% over the past month and +140.97% over the last year.

About Global Blood Therapeutics Inc (GBT:NSD)

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also eva ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD75.53B 24.40 16.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD68.27B 12.89 9.72
MRNA Moderna Inc

N/A

USD66.97B 5.32 3.83
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.59B 3.11 1.77
SGEN Seagen Inc

N/A

USD31.38B 55.02 -46.75
RPRX Royalty Pharma Plc

N/A

USD29.88B 43.33 20.93
ALNY Alnylam Pharmaceuticals Inc

N/A

USD28.07B N/A -36.52
GMAB Genmab AS

N/A

USD24.11B 75.33 6.42
ARGX argenx NV ADR

N/A

USD20.75B N/A -20.02

ETFs Containing GBT

Symbol Name Weight Mer Price(Change) Market Cap
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD0.14B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 128.05% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 128.05% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 140.97% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 140.97% 99% A+ 99% A+
Trailing 5 Years  
Capital Gain 134.21% 83% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 134.21% 83% B 82% B-
Average Annual (5 Year Horizon)  
Capital Gain -0.59% 51% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.59% 51% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 38.25% 72% C- 39% F
Risk Adjusted Return -1.55% 51% F 41% F
Market Capitalization 4.50B 94% A 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.22 38% F 54% F
Price/Book Ratio 38.10 4% F 3% F
Price / Cash Flow Ratio -17.53 88% B+ 81% B-
EV/EBITDA -16.14 95% A 88% B+
Management Effectiveness  
Return on Equity -148.56% 19% F 9% F
Return on Invested Capital -42.95% 61% D- 23% F
Return on Assets -25.18% 53% F 17% F
Debt to Equity Ratio 295.53% 7% F 8% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 8.56 24% F 17% F
Short Percent 14.30% 12% F 12% F
Beta 0.83 71% C- 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.